Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Immuneering Corporation Market Cap
Based on ratings from 0 stock analysts, the Immuneering Corporation stock price is expected to increase by 411.87% in 12 months. This is calculated by using the average 12-month stock price forecast for Immuneering Corporation. The lowest target is $1.5 and the highest is $25. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned IMRX 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Immuneering Corporation to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on IMRX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of IMRX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Ami Fadia Needham | Buy | $15 | Reiterates | Sep 13, 2024 |
| Ami Fadia Needham | Buy | $15 | Reiterates | Aug 7, 2024 |
| Geulah Livshits Chardan Capital | Buy | $12 | Maintains | Aug 7, 2024 |
| Ami Fadia Needham | Buy | $15 | Reiterates | May 8, 2024 |
| Ami Fadia Needham | Buy | $15 | Reiterates | Apr 12, 2024 |
| Graig Suvannavejh Mizuho | Buy | $8 | Maintains | Apr 2, 2024 |
| Ami Fadia Needham | Buy | $15 | Maintains | Mar 15, 2024 |
| Yaron Werber TD Cowen | Market Perform | Downgrade | Mar 15, 2024 | |
| Geulah Livshits Chardan Capital | Buy | $16 | Maintains | Mar 15, 2024 |
| Michael Yee Jefferies | Hold | $3 | Downgrade | Mar 15, 2024 |
| Michael Schmidt Guggenheim | Neutral | Downgrade | Mar 14, 2024 | |
| Ami Fadia Needham | Buy | $20 | Reiterates | Mar 11, 2024 |
| Jay Olson Oppenheimer | Outperform | $25 | Reiterates | Mar 5, 2024 |
| Ami Fadia Needham | Buy | $20 | Reiterates | Mar 4, 2024 |
| Ami Fadia Needham | Buy | $20 | Reiterates | Feb 1, 2024 |
| Ami Fadia Needham | Buy | $20 | Initiates | Dec 1, 2023 |
| Mark Breidenbach Oppenheimer | Outperform | $25 | Reiterates | Aug 8, 2023 |
| Geulah Livshits Chardan Capital | Buy | $22 | Reiterates | Aug 7, 2023 |
| Jeffrey Hung Morgan Stanley | Equal-Weight | $14 | Maintains | Aug 4, 2023 |
| Mark Breidenbach Oppenheimer | Outperform | $25 | Assumes | Jun 26, 2023 |
When did it IPO
2021
Staff Count
66
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Market Cap
$65.8M
In 2023, IMRX generated $0 in revenue, which was a decrease of -100.00% from the previous year. This can be seen as a signal that IMRX's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 16 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Immuneering stock increased by 41% after its lead drug combination demonstrated superior initial efficacy for first-line pancreatic cancer treatment in a mid-stage study.
Why It Matters - Immuneering's stock surge indicates strong market confidence in its drug's potential, likely enhancing investor interest and future valuations in biotech.
Thu, 12 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Immuneering reported positive initial Phase 2a results for IMM-1-104 combined with chemotherapy, showing complete and partial responses in first-line treatment.
Why It Matters - Positive Phase 2a data for IMM-1-104 suggests potential for effective cancer treatment, potentially boosting Immuneering's stock value and attracting investor interest in biotech innovation.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Immuneering Corporation (Nasdaq: IMRX) reported strong enrollment in its IMM-1-104 Phase 2a Trial, expecting initial data in 2H 2024. The drug received FDA Fast Track designation for pancreatic cancer.
Why It Matters - Positive trial enrollment and FDA Fast Track designation for IMM-1-104 suggest potential for accelerated market entry and increased investor interest, especially in the oncology sector.
Thu, 01 Aug 2024
Sentiment - POSITIVE
Source - InvestorPlace
Summary - Biotech stocks are experiencing significant movements today, with a focus on small-cap growth names like Immuneering (NASDAQ: IMRX), attracting investor interest.
Why It Matters - Increased interest in small-cap biotech stocks like Immuneering signals potential growth opportunities and shifts in investor sentiment, impacting market dynamics and stock valuations.
Wed, 31 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Immuneering Corporation's IMM-1-104 received FDA Fast Track designation for first-line PDAC treatment, aiming for accelerated submission. Phase 2a trial data expected in H2 2024.
Why It Matters - Fast Track designation for IMM-1-104 enhances its development timeline for treating PDAC, potentially increasing its market value and attracting investor interest in Immuneering Corporation.
Tue, 09 Jul 2024
Sentiment - NEUTRAL
Source - 24/7 Wall Street
Summary - Equities remain strong as the third quarter progresses, indicating continued bullish sentiment in the market.
Why It Matters - Strong market momentum suggests continued investor confidence, potentially driving stock prices higher and creating opportunities for gains in equity investments.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
